Phio Pharmaceuticals Corp. (PHIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 17, 2024, details the results of Phio Pharmaceuticals Corp.'s 2024 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
Stockholders approved four key proposals at the Annual Meeting:
- Director Elections: Five nominees (Robert J. Bitterman, Patricia A. Bradford, Robert L. Ferrara, Jonathan E. Freeman, and Curtis A. Lockshin) were elected to serve until the 2025 Annual Meeting.
- Auditor Ratification: BDO USA, P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- Reverse Stock Split: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-9. The exact ratio and effective date are to be determined by the Board of Directors and will be reported in a future 8-K.
- Equity Plan Amendment: The 2020 Long Term Incentive Plan was amended to increase the number of shares available for issuance by 500,000, bringing the total to 725,500 shares.
As of the record date (April 26, 2024), the company had 4,591,700 shares of common stock issued and outstanding. A total of 2,204,345 shares were present or represented at the meeting.
Guidance, Outlook, and Risks
The filing does not provide management commentary on financial guidance, future outlook, or specific risk factors. The primary contingency noted is the pending determination of the specific reverse stock split ratio and effective date by the Board of Directors.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board of Directors in a subsequent filing.
- Review the definitive proxy statement (Schedule 14A filed May 8, 2024) for detailed descriptions of the director nominees and the amended 2020 Plan.
- Monitor future filings for the implementation of the reverse stock split and its impact on share count and trading price.